Covered with room, growing fast, barely levered. Second-quarter normalized funds available for distribution were $0.51 a share against a $0.39 quarterly dividend — about a 76% payout — and normalized FFO was also $0.51. The dividend itself was raised in 2026 from $0.335 to $0.39, up about 16%, and management raised full-year 2026 guidance at the second-quarter report to normalized FFO of $2.03 to $2.06 and normalized FAD of $2.01 to $2.04, implying roughly 16% and 15% growth over 2025 at the midpoints. The balance sheet barely needs the dividend to be defended: net debt to annualized normalized run-rate EBITDA was 1.0× at June 30, 2026, fixed-charge coverage was 9.9×, and there were no scheduled debt maturities before 2028.
Key risk: Growth funded with equity — rapid investment has been paid for with share issuance, including unsettled forward sales, so the per-share growth this grade relies on depends on new investments earning more than the dilution they carry. If deal yields fall or shares must be sold at lower prices, per-share FAD growth slows first.
Changes if: Normalized FAD falls toward the $0.39 quarterly dividend, leverage rises materially above the 1.0× reported at June 30, 2026, or guidance for normalized FAD is cut — any of those would break the cushion this grade rests on.
- ✓FAD coverage check: Second-quarter normalized FAD of $0.51 a share covered the $0.39 dividend at about 76%, and full-year normalized FAD guidance of $2.01 to $2.04 covers the $1.56 annual dividend with room.
- ✓Leverage check: Net debt to annualized normalized run-rate EBITDA was 1.0× at June 30, 2026, well below a typical REIT range, with 9.9× fixed-charge coverage and no scheduled debt maturities before 2028.
- ✓Growth check: The dividend rose from $0.335 to $0.39 during 2026, about 16%, and raised full-year guidance implies about 16% normalized FFO growth and about 15% normalized FAD growth over 2025 at the midpoints.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.